Cytogam (Cytomegalovirus Immune Globulin Intravenous) Market Report 2026

Cytogam (Cytomegalovirus Immune Globulin Intravenous) Market Overview

• The Cytogam (Cytomegalovirus Immune Globulin Intravenous) market growth in the historic period has been driven by high cmv risk in transplant recipients, established use of immune globulins • Market expansion is supported by growth in transplant volumes, increasing immunosuppressed populations • Growth Driver: Growth In Transplant Procedures Driving The Demand For Cytogam (Cytomegalovirus Immune Globulin Intravenous) In Organ Transplantation • Market Trend: Focus On Innovation And Regulatory Approvals To Gain Competitive Edge • North America was the largest region in 2025.

The key promising market opportunities in the cytogam (cytomegalovirus immune globulin intravenous) market include: • Specialty Pharmacies (Segmentation By By Distribution Channel) → Expected gain of $0.04 Billion • Hospital Pharmacies (Segmentation By By Distribution Channel) → Expected gain of $0.001 Billion

What Is Covered Under Cytogam (Cytomegalovirus Immune Globulin Intravenous) Market?

Cytogam (Cytomegalovirus Immune Globulin Intravenous) is an intravenous medication used to prevent and treat Cytomegalovirus (CMV) infections in immunocompromised patients, such as organ transplant recipients. It contains antibodies derived from human plasma, which help fight the CMV virus. It is typically administered to prevent CMV reactivation or infection. The treatment is often used in combination with antiviral therapies. It helps reduce the risk of CMV-related complications in vulnerable patients. The main dosage forms of cytogam (cytomegalovirus immune globulin intravenous) are intravenous (IV) injection and other forms (if applicable). Intravenous (IV) injection is a method of administering Cytogam (cytomegalovirus immune globulin intravenous) directly into the bloodstream through a vein. The clinical indication are prevention of cytomegalovirus (CMV) disease in transplant recipients, prophylaxis in solid organ transplant patients, prophylaxis in hematopoietic stem cell transplant patients, use in pregnant women with primary CMV infection. The patient population includes adult patients and pediatric patients, and the distribution channel includes hospital pharmacies, outpatient clinics, and specialty pharmacies.

What Is The Cytogam (Cytomegalovirus Immune Globulin Intravenous) Market Growth Forecast?

The growth in the forecast period can be attributed to growth in transplant volumes, increasing immunosuppressed populations, expansion of antiviral combination therapies, improved cmv screening, rising specialty pharmacy access. Major trends in the forecast period include rising use in transplant patients, increased demand for cmv prophylaxis, combination therapy with antivirals, hospital based immunoglobulin administration, focus on immunocompromised populations.

What Are The Drivers Of The Cytogam (Cytomegalovirus Immune Globulin Intravenous) Market?

The rise in the number of transplant procedures is expected to propel the growth of the cytogam (cytomegalovirus immune globulin intravenous) market going forward. Transplant procedures refer to medical surgeries where an organ or tissue is transferred from one person (donor) to another (recipient) to replace a damaged or non-functioning organ. The rise in the number of transplant procedures can be attributed to several key factors such as an increase in organ donations, advancements in medical technology, and improved treatment options. Cytogam (cytomegalovirus immune globulin intravenous) is primarily used to prevent or treat cytomegalovirus (CMV) infections in immunocompromised patients, especially those undergoing organ transplants. For instance, in January 2024, according to OPTN (Organ Procurement and Transplantation Network), a US-based government department, there were 46,632 organ transplants performed by both living and deceased donors in 2023. This represents an 8.7% increase over 2022. Therefore, the rise in the number of transplant procedures is driving the growth of the cytogam cytomegalovirus immune globulin intravenous) market. The rising chronic disease is expected to propel the growth of the cytogam (cytomegalovirus immune globulin intravenous) market going forward. A chronic disease is a long-lasting health condition that progresses slowly and usually persists for years. Chronic diseases are increasing mainly due to unhealthy lifestyle habits such as poor diet and physical inactivity. Cytogam (cytomegalovirus immune globulin intravenous) is used in chronic disease care by strengthening immune defense against CMV infections in high-risk patients, especially those with long-term immunocompromised conditions. For instance, in June 2023, the Institute for Health Metrics and Evaluation, a US-based public health research institute, reported that over half a billion people globally were living with diabetes. This number is expected to more than double, reaching 1.3 billion people by 2050. Therefore, the rising chronic disease will drive the growth of the cytogam (cytomegalovirus immune globulin intravenous) industry.

How Will The Drivers Impact Growth In The Global Cytogam (Cytomegalovirus Immune Globulin Intravenous) Market?

• Rising Global Organ Transplant Procedures (High) – During the forecast period, the rising global organ transplant procedures are expected to become a key growth driver for the cytogam (cytomegalovirus immune globulin intravenous) market by 2035. The increasing number of kidney, liver, heart, lung, and pancreas transplant procedures is expanding the population at risk of CMV infection and reactivation. Transplant recipients require comprehensive prophylactic care to prevent opportunistic infections that can compromise graft function and patient survival. Healthcare providers are increasingly incorporating CMV immune globulin therapies into post-transplant management programs, particularly for high-risk donor-recipient combinations. Expanding transplant infrastructure and improving long-term transplant outcomes are further supporting product adoption. • Increasing Prevalence of CMV Infection in Immunocompromised Patients (Medium) – During the forecast period, the increasing prevalence of CMV infection in immunocompromised patients is expected to emerge as a major factor driving the expansion of the cytogam (cytomegalovirus immune globulin intravenous) market by 2035. CMV remains a significant clinical challenge among transplant recipients and patients receiving immunosuppressive therapies, creating sustained demand for preventive interventions. CMV-associated complications can lead to graft rejection, organ dysfunction, prolonged hospitalization, and increased healthcare expenditures. Medical institutions are therefore strengthening CMV surveillance and prevention programs to improve clinical outcomes and reduce disease burden. Growing awareness of CMV-related risks and expanding patient monitoring practices are further accelerating therapy utilization. • Growing Adoption of Combination CMV Prophylaxis Therapies (Low) – During the forecast period, the growing adoption of combination CMV prophylaxis therapies is expected to act as a key growth catalyst for the cytogam (cytomegalovirus immune globulin intravenous) market by 2035. The use of cytogam alongside antiviral agents is becoming increasingly common as healthcare providers seek more effective prevention strategies for high-risk transplant recipients. Combination approaches help reduce CMV disease incidence, limit viral replication, and support improved graft survival rates. Hospitals and transplant centers are integrating immune globulin therapies into standardized treatment pathways to enhance patient outcomes and lower post-transplant complications. Continued advances in transplant medicine and infection prevention protocols are further supporting broader clinical acceptance.

How Will The Restraints Impact Growth In The Global Cytogam (Cytomegalovirus Immune Globulin Intravenous) Market?

• High Treatment and Administration Costs (High) – During the forecast period, the cytogam therapy involves high acquisition and administration expenses, which can limit widespread adoption, particularly in cost-sensitive healthcare systems. The product requires intravenous infusion under medical supervision, increasing hospitalization and monitoring costs. Repeated dosing schedules following transplantation further elevate overall treatment expenditure. Many healthcare providers in developing economies may prioritize lower-cost antiviral alternatives over immune globulin therapy. Reimbursement limitations and budget constraints within hospitals can also reduce utilization rates. The high economic burden associated with biologic therapies remains a significant barrier to broader market penetration. • Availability of Alternative Antiviral Therapies (Medium) – During the forecast period, the growing use of newer antiviral drugs such as letermovir, valganciclovir, and maribavir is restraining Cytogam demand in certain clinical settings. These therapies offer targeted CMV prevention and treatment with more convenient dosing regimens compared to intravenous immune globulin administration. Physicians may increasingly favor oral or less resource-intensive therapies for prophylaxis. Emerging antiviral agents with improved efficacy and resistance profiles are intensifying competition within CMV management. Advances in antiviral drug development may reduce dependence on adjunctive immune globulin therapies over time. The expanding therapeutic landscape could limit long-term market expansion for Cytogam products. • Limited Clinical Consensus in Certain Indications (Low) – During the forecast period, the although Cytogam is widely used in transplant-associated CMV prophylaxis, some clinical guidelines indicate insufficient evidence for routine use in all transplant populations. Certain studies have shown mixed outcomes regarding the added benefit of CMV immune globulin alongside antiviral prophylaxis. Variability in physician preferences and institutional protocols creates inconsistent adoption patterns across healthcare systems. Some transplant centers reserve Cytogam only for very high-risk patients rather than universal prophylaxis. Lack of standardized treatment protocols in hematopoietic stem cell transplantation also limits broader uptake. Continued debate regarding cost-effectiveness and clinical benefit may restrain market growth.

Key Players In The Global Cytogam (Cytomegalovirus Immune Globulin Intravenous) Market

Major companies operating in the cytogam (cytomegalovirus immune globulin intravenous) market are CSL Behring

Global Cytogam (Cytomegalovirus Immune Globulin Intravenous) Market Trends and Insights

Major companies operating in the cytogam (cytomegalovirus immune globulin intravenous) market are focusing on innovative approaches, such as manufacturing technology transfer to gain a competitive edge. Manufacturing technology transfer refers to the process of transferring the knowledge, processes, and techniques required to produce a product from one site or company to another, ensuring the new facility can manufacture the product with the same quality and standards as the original. For instance, in May 2023, Kamada Ltd., an Israel-based biopharmaceutical company, launched commercial sale of CYTOGAM in the US, following FDA approval of the technology transfer from CSL Behring. This product, indicated for the prevention of CMV disease in transplant patients, is the only FDA-approved IgG product for this purpose. Kamada's manufacturing facility in Beit Kama, Israel, now produces CYTOGAM, with availability in Canada expected later this year.

What Defines the Cytogam (Cytomegalovirus Immune Globulin Intravenous) Market?

The cytogam (cytomegalovirus immune globulin intravenous) market consists of sales of Cytogam (Cytomegalovirus Immune Globulin Intravenous) 500 mg/10 mL and Cytogam (Cytomegalovirus Immune Globulin Intravenous) 1000 mg/20 mL. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cytogam (Cytomegalovirus Immune Globulin Intravenous) Market Report 2026?

The cytogam (cytomegalovirus immune globulin intravenous) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cytogam (cytomegalovirus immune globulin intravenous) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.